Assessing oncologic benefit in clinical trials of immunotherapy agents (Q37710860)

22 August 2017

1 reference

title

Assessing oncologic benefit in clinical trials of immunotherapy agents (English)

1 reference

22 August 2017

1 reference

R K Hales

1

1 reference

22 August 2017

J Banchereau

2

1 reference

22 August 2017

A Ribas

3

1 reference

22 August 2017

A A Tarhini

4

1 reference

22 August 2017

J S Weber

5

1 reference

22 August 2017

B A Fox

6

1 reference

22 August 2017

C G Drake

7

1 reference

22 August 2017

17 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

21

1 reference

22 August 2017

10

1 reference

22 August 2017

1944-1951

1 reference

Assessing tumor-related signs and symptoms to support cancer drug approval

22 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ048

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ048

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ048

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ048

Spinning molecular immunology into successful immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ048

Checkpoint blockade in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ048

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ048

Restoring function in exhausted CD8 T cells during chronic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ048

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ048

The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ048

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ048

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ048

Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ048

Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ048

A strategic framework for novel drug development in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ048

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ048

Proposal for the use of progression-free survival in unblinded randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ048

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ048

Randomized phase II designs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ048

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ048

Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma

21 January 2018

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2007.25.18_SUPPL.8525

Identifiers

DOI

10.1093/ANNONC/MDQ048

1 reference

22 August 2017

1 reference